Juno Pharmaceuticals
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Revenues | 2.4m | 2.4m | 2.9m | 2.9m |
% growth | - | - | 21 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Growth Equity VC | ||
Total Funding | - |
Related Content
Recent News about Juno Pharmaceuticals
EditJuno Pharmaceuticals specializes in providing innovative injectable pharmaceutical solutions to hospitals and healthcare specialists. Operating primarily in the Australian market, Juno focuses on the sales and distribution of high-quality sterile injectable products. The company collaborates with Bridgewest to leverage their manufacturing capabilities, ensuring supply stability and fostering innovation. Juno serves healthcare providers, including hospitals and specialists, by offering a range of biologic and biosimilar medicines that are essential for treating disabling and life-threatening diseases. The business model revolves around the sale of these specialized pharmaceuticals, generating revenue through direct sales to healthcare institutions. Juno's commitment to corporate responsibility and its values of being entrepreneurial, dynamic, and trusted underpin its operations and partnerships. The company aims to increase patient access to lifesaving medicines while adding value to the healthcare system.
Keywords: injectable solutions, healthcare specialists, biologic medicines, biosimilars, sterile manufacturing, supply stability, innovation, Australian market, corporate responsibility, patient access.